GlassScriptPhysician profile
Arda Akoluk
NPI 1538666722
$777.17
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $206 · 2023: $265 · 2024: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $534 · Education: $37.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $534.19 |
| Education | $37.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $163.43 | 2022-2024 | Ultomiris |
| Travere Therapeutics, INC. | $151.57 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $119.08 | 2022 | |
| Sanofi-Aventis U.S. LLC | $113.53 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.08 | 2023 | |
| Glaxosmithkline, LLC. | $37.98 | 2023 | Jesduvroq, Benlysta |
| Opko Pharmaceuticals, LLC | $37.39 | 2023-2024 | Rayaldee |
| Amgen INC. | $25.76 | 2024 | Tavneos |
| Alnylam Pharmaceuticals INC. | $25.50 | 2023 | Oxlumo |
| Fresenius USA Marketing, INC. | $24.84 | 2024 | Velphoro |
| Novo Nordisk INC | $22.01 | 2024 | Rivfloza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arda Akoluk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.